Health News Releases

June 20, 2014 17:30

New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation

For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ st

June 20, 2014 11:35

Quintiles and Modern Marketing Concepts Collaborate to Launch Innovative Marketing Analytics Platform

Quintiles (www.quintiles.com) and Modern Marketing Concepts (MMC, Inc., www.mmcweb.com) today announced the launch of a new marketing analytics platform that enables Quintiles to optimize sales and ma

June 18, 2014 12:05

Pathway Genomics Co-Hosts Fundraiser Benefiting Susan G. Komen

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, last week co-hosted a fundraiser benefiting Susan G. Komen. J

June 17, 2014 13:15

Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

For Non-U.S. and Non-U.K. Media Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin, a sodium glucose

June 16, 2014 18:45

22nd Century Group to be Added to Russell 3000, Russell 2000, Russell Global and Russell Microcap Indexes

22nd Century Group, Inc. (NYSE MKT: XXII, http://finance.yahoo.com/q?s=xxii) today announced that the Company will join the Russell 3000, Russell 2000, Russell Global and Russell Microcap Indexes when

June 16, 2014 16:35

New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia

For media outside of the US/UK only Acute myeloid leukaemia (AML) is a devastating form of blood cancer that mainly affects people over 60 years old.[1] For older patients who receive chemotherapy,

June 16, 2014 14:10

Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from a long-term (52-week) phase III trial of OTEZLA, the Company’s oral, selective

June 16, 2014 14:05

Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company’s o

June 16, 2014 01:05

Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition

Non-US and Non-UK The first insights from IntroDia™ presented at the American Diabetes Association's (ADA) 74th Scientific Sessions®, showed that over three quarters (76-100 percent across 26 count

June 12, 2014 14:55

U.S. Patent Allowed For 22nd Century Group’s Technology to Regulate Nicotine Levels in Tobacco

22nd Century Group, Inc. (NYSE MKT:XXII) today announced that on June 9, 2014 the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance to the Company for technology that reduces nicot

June 10, 2014 15:55

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to have 43 Presentations Featured at the American Diabetes Association’s 74th Scientific Sessions®

For Non-US and Non-UK Media More than 40 presentations including posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly and

June 10, 2014 14:00

Quintiles Named ‘Overwhelming Leader’ in Phase I Market Report

For the second year in a row, Quintiles has been named the CRO industry leader in Phase I services according to respondents in Industry Standard Research’s (ISR) report, CRO Quality Benchmarking Phase

June 09, 2014 14:25

MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association

MSD, known as Merck (NYSE:MRK) in the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA® (sitagliptin) and for its investigational once

June 09, 2014 13:45

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prev

June 09, 2014 13:45

Quintiles Honored for IT Innovation, Named to 2014 CIO 100

Quintiles, the world’s largest biopharmaceutical services provider, has been named to the 2014 CIO 100. Each year, CIO magazine identifies and honors 100 organizations that have distinguished themselv

June 09, 2014 11:05

Quintiles Executive to Present at the 2014 Wells Fargo Healthcare Conference

Quintiles CFO Kevin Gordon will present at the 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014, in Boston’s InterContinental Hotel. The Quintiles presentation will begin at 1:10 p.

June 05, 2014 18:15

EMA accepts marketing authorisation application for nintedanib* in IPF

For non-US health media only Boehringer Ingelheim today announced that the application for marketing authorisation of nintedanib*, a tyrosine kinase inhibitor (TKI), for the treatment of idiopathic

June 05, 2014 16:30

New Study Reported Prevena™ Therapy Patients Had a Significantly Lower Infection Rate Following Cardiac Surgery Compared to Control Group

Kinetic Concepts, Inc. (www.kci1.com/KCI1/home) announced today that a new study, published in the International Wound Journal, showed the Prevena™ Incision Management System used over closed incision

June 03, 2014 21:05

Eppendorf Announces New BioBLU® 5c and 14c Adaptor Kits

Eppendorf is proud to announce a new addition to the BioBLU Single-use Vessel Adaptor Kit portfolio. The BioBLU 5c and 14c Adaptor Kits allow BioBLU 5c and 14c Single-use vessels to be used on and con

June 03, 2014 21:00

Pathway Genomics Launches BRCA1/2 Genetic Test with One for One Program

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BRCATrueTM, a next-generation

June 03, 2014 11:45

New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy

For Ex-US and Ex-UK Media only Boehringer Ingelheim today announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LU

June 03, 2014 11:35

Quintiles Named to the Fortune 500

Quintiles, the world’s largest biopharmaceutical services provider, has been named to the Fortune 500 (http://goo.gl/nKpkC6) list of largest U.S. companies ranked by revenue. “Being named to the Fo

June 02, 2014 10:15

Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014

Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of

May 29, 2014 10:30

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation

For media outside of the U.S., the UK & Canada only Boehringer Ingelheim announced today that the company has reached a comprehensive settlement of state and federal cases in the U.S. litigation re

May 28, 2014 16:50

Quintiles CEO Tom Pike to Present at Goldman Sachs 35th Annual Global Healthcare Conference

Quintiles CEO Tom Pike will present at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014 at the Terranea Resort in Rancho Palos Verdes, CA. The Quintiles presen

News by Region

News by Industry